Huadong Medicine Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Huadong Medicine has been growing earnings at an average annual rate of 0.9%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 4.6% per year. Huadong Medicine's return on equity is 14.2%, and it has net margins of 7.7%.
Belangrijke informatie
0.9%
Groei van de winst
0.9%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 7.0% |
| Inkomstengroei | 4.6% |
| Rendement op eigen vermogen | 14.2% |
| Nettomarge | 7.7% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital
Sep 23
Earnings Working Against Huadong Medicine Co., Ltd's (SZSE:000963) Share Price
Aug 05Huadong Medicine (SZSE:000963) Seems To Use Debt Rather Sparingly
Jun 28There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital
Jun 10Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Apr 21Market Cool On Huadong Medicine Co., Ltd's (SZSE:000963) Earnings
Apr 08Is Huadong Medicine (SZSE:000963) A Risky Investment?
Mar 16Opbrengsten en kosten
Hoe Huadong Medicine geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 41,707 | 3,212 | 8,246 | 1,379 |
| 30 Jun 24 | 41,204 | 3,101 | 8,297 | 1,356 |
| 31 Mar 24 | 40,920 | 2,946 | 8,028 | 1,287 |
| 31 Dec 23 | 40,624 | 2,839 | 8,091 | 1,271 |
| 30 Sep 23 | 40,251 | 2,707 | 7,928 | 1,069 |
| 30 Jun 23 | 39,902 | 2,592 | 7,817 | 1,008 |
| 31 Mar 23 | 38,897 | 2,550 | 7,889 | 962 |
| 01 Jan 23 | 37,715 | 2,499 | 7,652 | 1,016 |
| 30 Sep 22 | 36,494 | 2,388 | 7,104 | 1,040 |
| 30 Jun 22 | 35,582 | 2,342 | 6,758 | 1,109 |
| 31 Mar 22 | 34,599 | 2,248 | 6,443 | 1,079 |
| 01 Jan 22 | 34,563 | 2,302 | 6,633 | 980 |
| 30 Sep 21 | 34,110 | 2,324 | 6,675 | 964 |
| 30 Jun 21 | 34,202 | 2,389 | 6,898 | 885 |
| 31 Mar 21 | 33,982 | 2,431 | 6,810 | 883 |
| 31 Dec 20 | 33,683 | 2,820 | 6,992 | 927 |
| 30 Sep 20 | 33,319 | 2,991 | 6,891 | 1,051 |
| 30 Jun 20 | 33,858 | 2,948 | 6,923 | 1,084 |
| 31 Mar 20 | 34,339 | 3,053 | 6,964 | 1,179 |
| 31 Dec 19 | 35,446 | 2,813 | 6,921 | 1,073 |
| 30 Sep 19 | 35,087 | 2,671 | 6,615 | 952 |
| 30 Jun 19 | 33,587 | 2,570 | 6,092 | 911 |
| 31 Mar 19 | 32,532 | 2,515 | 5,706 | 771 |
| 31 Dec 18 | 30,663 | 2,267 | 5,132 | 706 |
| 30 Sep 18 | 29,585 | 2,099 | 4,978 | 652 |
| 30 Jun 18 | 29,066 | 2,031 | 4,690 | 726 |
| 31 Mar 18 | 28,519 | 1,895 | 4,554 | 555 |
| 31 Dec 17 | 27,832 | 1,780 | 4,359 | 462 |
| 30 Sep 17 | 27,911 | 1,740 | 4,298 | 276 |
| 30 Jun 17 | 27,227 | 1,665 | 4,371 | 0 |
| 31 Mar 17 | 26,363 | 1,556 | 4,254 | 0 |
| 31 Dec 16 | 25,380 | 1,447 | 4,096 | 0 |
| 30 Sep 16 | 24,491 | 1,365 | 4,074 | 0 |
| 30 Jun 16 | 23,588 | 1,253 | 3,978 | 0 |
| 31 Mar 16 | 22,682 | 1,188 | 3,749 | 0 |
| 31 Dec 15 | 21,727 | 1,097 | 3,512 | 0 |
| 30 Sep 15 | 20,923 | 1,136 | 3,292 | 0 |
| 30 Jun 15 | 20,220 | 1,034 | 3,067 | 0 |
| 31 Mar 15 | 19,656 | 899 | 2,997 | 0 |
| 31 Dec 14 | 18,947 | 757 | 2,772 | 0 |
| 30 Sep 14 | 18,208 | 655 | 2,672 | 0 |
| 30 Jun 14 | 17,724 | 631 | 2,520 | 0 |
| 31 Mar 14 | 17,237 | 617 | 2,395 | 0 |
| 31 Dec 13 | 16,718 | 575 | 2,267 | 0 |
Kwaliteitswinsten: 000963 has high quality earnings.
Groeiende winstmarge: 000963's current net profit margins (7.7%) are higher than last year (6.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 000963's earnings have grown by 0.9% per year over the past 5 years.
Versnelling van de groei: 000963's earnings growth over the past year (18.7%) exceeds its 5-year average (0.9% per year).
Winst versus industrie: 000963 earnings growth over the past year (18.7%) exceeded the Healthcare industry -5.7%.
Rendement op eigen vermogen
Hoge ROE: 000963's Return on Equity (14.2%) is considered low.